As of 2025-01-15, the EV/EBITDA ratio of Novavax Inc (NVAX) is -4.99. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Novavax's latest enterprise value is 1,022.01 mil USD. Novavax's TTM EBITDA according to its financial statements is -204.92 mil USD. Dividing these 2 quantities gives us the above Novavax EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 15.0x - 17.3x | 15.8x |
| Forward P/E multiples | 17.8x - 32.9x | 24.8x |
| Fair Price | (20.70) - (20.01) | (23.78) |
| Upside | -343.4% - -335.2% | -379.6% |
| Date | EV/EBITDA |
| 2025-01-14 | -5.07 |
| 2025-01-13 | -5.07 |
| 2025-01-10 | -5.62 |
| 2025-01-08 | -5.85 |
| 2025-01-07 | -6.80 |
| 2025-01-06 | -5.97 |
| 2025-01-03 | -5.26 |
| 2025-01-02 | -5.04 |
| 2024-12-31 | -4.62 |
| 2024-12-30 | -4.54 |
| 2024-12-27 | -4.81 |
| 2024-12-26 | -4.96 |
| 2024-12-24 | -4.99 |
| 2024-12-23 | -5.09 |
| 2024-12-20 | -5.14 |
| 2024-12-19 | -5.12 |
| 2024-12-18 | -5.08 |
| 2024-12-17 | -5.37 |
| 2024-12-16 | -5.55 |
| 2024-12-13 | -5.46 |
| 2024-12-12 | -5.39 |
| 2024-12-11 | -5.23 |
| 2024-12-10 | -5.19 |
| 2024-12-09 | -5.43 |
| 2024-12-06 | -5.33 |
| 2024-12-05 | -4.83 |
| 2024-12-04 | -4.83 |
| 2024-12-03 | -4.91 |
| 2024-12-02 | -5.19 |
| 2024-11-29 | -5.16 |
| 2024-11-27 | -5.08 |
| 2024-11-26 | -5.18 |
| 2024-11-25 | -5.62 |
| 2024-11-22 | -4.96 |
| 2024-11-21 | -4.62 |
| 2024-11-20 | -4.64 |
| 2024-11-19 | -4.59 |
| 2024-11-18 | -4.46 |
| 2024-11-15 | -4.06 |
| 2024-11-14 | -3.98 |
| 2024-11-13 | -4.41 |
| 2024-11-12 | -4.95 |
| 2024-11-11 | -5.38 |
| 2024-11-08 | -5.30 |
| 2024-11-07 | -5.51 |
| 2024-11-06 | -5.34 |
| 2024-11-05 | -5.72 |
| 2024-11-04 | -5.47 |
| 2024-11-01 | -5.65 |
| 2024-10-31 | -5.85 |